Between the Biotech Waves cover image

Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse

Between the Biotech Waves

CHAPTER

The Importance of Pricing in an IPO

The top three questions that Board of Management seems used to ask us were, how come I'm not getting valuation credit or how can I get valuation credit for early stage program XYZ. Now you're very much hearing questions that are grounded in the market that we were currently operating in. How do I ensure that my existing shareholders fully appreciate all the value that we're building here and will seem to be supporters? And then as they enter these conversations with public market or crossover investors, I think they're being very forward in laying out their logic for when they think an IPO window may present itself.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner